2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting

In a prospective study from China, a novel noninvasive stool DNA methylation assay showed promise for the early detection of multiple gastrointestinal (GI) cancers.

In an interim analysis of the K-DETEK study, a noninvasive blood test was able to detect early-stage cancer and identify tumour location in asymptomatic individuals in Vietnam.

Prostate cancer treatment upends sexual function in men, but the good news is that supervised resistance and aerobic workout can counter these sexual side effects, according to a study presented at ASCO Breakthrough 2023.

A dexamethasone-free regimen helps improve control of nausea and vomiting in patients receiving “highly emetogenic” chemotherapy, with the antiemetic effect being superior to that of a dexamethasone-based regimen, according to the results of a phase III trial presented at ASCO Breakthrough 2023.

Certain comorbidities such as hypertension and diabetes mellitus (DM), along with locally advanced stage at diagnosis and systemic treatment received (ie, doxorubicin), are significantly associated with tumour recurrences among patients with breast cancer, according to a study presented at the recent ASCO Breakthrough 2023.

A trend towards a favourable overall (OS) and disease-free survival (DFS) at 21 months follow-up has been observed among patients with early breast cancer enrolled to a government program that grants medicines access to indigent individuals, reports a study presented at ASCO Breakthrough 2023.